FDA Clearance Tracker · K072939
HE4 EIA, MODEL: 404-10 US
Last checked: Nov 20, 2026Latest source record: Jun 9, 2008 (this decision)Source: openFDAMethods & limitations
Decided
Jun 9, 2008
Substantially Equivalent
Time to decision
236 days
Received Oct 17, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K072939
- Device name
- HE4 EIA, MODEL: 404-10 US
- Applicant
- Fujirebio Diagnostics,Inc.
- Applicant location
- Malvern, PA
- Received
- Oct 17, 2007
- Decided
- Jun 9, 2008
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.6010
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code OIU (Test, Epithelial Ovarian Tumor Associated Antigen (He4)).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K072939
- The applicant filed a summary instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Fujirebio Diagnostics,Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250925 · Decided Dec 16, 2025 · 264 days after receipt
Device type: Cytokeratin Fragments 21-1 Eia Kit (OVK) · Laboratory Medicine & Pathology
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioBreakthrough510(k)
K242706 · Decided May 16, 2025 · 249 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
- Lumipulse G ß-Amyloid Ratio (1-42/1-40)New device typeBreakthroughDe Novo
DEN200072 · Decided May 4, 2022 · 530 days after receipt
Device type: AlzheimerS Disease Pathology Assessment Test (QSE) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.